JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Search

Danaher Corp

Aperta

SettoreSettore sanitario

199.67 -0.44

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

199.08

Massimo

200.67

Metriche Chiave

By Trading Economics

Entrata

-399M

555M

Vendite

195M

5.9B

P/E

Media del settore

41.835

34.393

EPS

1.8

Rendimento da dividendi

0.6

Margine di Profitto

9.35

Dipendenti

61,000

EBITDA

-1B

760M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+19.21% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

0.60%

2.54%

Utili prossimi

21 ott 2025

Prossima data del Dividendo

24 ott 2025

Prossima data del' Ex Dividendo

26 set 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

6.8B

141B

Apertura precedente

200.11

Chiusura precedente

199.67

Notizie sul Sentiment di mercato

By Acuity

44%

56%

147 / 374 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Danaher Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

22 lug 2025, 11:32 UTC

Utili

Danaher Posts Lower 2Q Profit, Names Next CFO -- Update

22 lug 2025, 10:42 UTC

Utili

Danaher Posts Higher 2Q Sales, Lower Profit

22 apr 2025, 10:34 UTC

Utili

Danaher 1Q Results Decline But Top Estimates

5 feb 2025, 12:54 UTC

Utili

Johnson Controls Names Weidemanis CEO, Logs 1Q Income Growth

29 gen 2025, 11:44 UTC

Utili

Danaher 4Q Revenue Rises on Gains in Life Sciences, Biotech

22 lug 2025, 10:03 UTC

Utili

Danaher Had Seen 2025 Adjusted EPS $7.60-$7.75 >DHR

22 lug 2025, 10:03 UTC

Utili

Danaher Raises 2025 View To Adj EPS $7.70-Adj EPS $7.80 >DHR

22 lug 2025, 10:02 UTC

Utili

Danaher Still Sees 2025 Core Revenue Up About 3% >DHR

22 lug 2025, 10:01 UTC

Utili

Danaher Sees 3Q Core Revenue Up Low-Single Digits >DHR

22 lug 2025, 10:00 UTC

Utili

Danaher 2Q Operating Cash Flow $1.3B, Free Cash Flow $1.1B >DHR

22 lug 2025, 10:00 UTC

Utili

Danaher 2Q Net $555M >DHR

22 lug 2025, 10:00 UTC

Utili

Danaher 2Q Sales $5.9B >DHR

22 lug 2025, 10:00 UTC

Utili

Danaher 2Q Adj EPS $1.80 >DHR

22 lug 2025, 10:00 UTC

Utili

Danaher 2Q EPS 77c >DHR

22 lug 2025, 09:34 UTC

Azioni calde

Stocks to Watch Tuesday: Coca-Cola, GM, AstraZeneca, NXP -- WSJ

14 lug 2025, 16:12 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

22 apr 2025, 10:02 UTC

Utili

Danaher Still Sees 2025 Adjusted Core Revenue Up About 3% >DHR

22 apr 2025, 10:02 UTC

Utili

Danaher Sees 2025 Adj EPS $7.60-Adj EPS $7.75 >DHR

22 apr 2025, 10:02 UTC

Utili

Danaher Sees 2Q Adjusted Core Revenue Up Low-Single Digits >DHR

22 apr 2025, 10:01 UTC

Utili

Danaher: Macro Backdrop Has Become More Dynamic Since Start of Year >DHR

22 apr 2025, 10:01 UTC

Utili

Danaher 1Q Adjusted Core Revenue Flat >DHR

22 apr 2025, 10:00 UTC

Utili

Danaher 1Q Operating Cash Flow $1.3B, Adjusted Free Cash Flow $1.1B >DHR

22 apr 2025, 10:00 UTC

Utili

Danaher 1Q Adj EPS $1.88 >DHR

22 apr 2025, 10:00 UTC

Utili

Danaher 1Q EPS $1.32 >DHR

22 apr 2025, 10:00 UTC

Utili

Danaher 1Q Sales $5.74B >DHR

22 apr 2025, 10:00 UTC

Utili

Danaher 1Q Net $954M >DHR

29 gen 2025, 15:25 UTC

Discorsi di Mercato
Utili

Danaher's 2025 Sales Guidance Disappoints -- Market Talk

29 gen 2025, 13:56 UTC

Notizie principali
Utili

Danaher Had an Unusual Quarter. The Stock Is Down. -- Barrons.com

29 gen 2025, 11:08 UTC

Utili

Danaher Sees 2025 Bioprocessing Core Revenue Growth 6%-7% >DHR

29 gen 2025, 11:07 UTC

Utili

Danaher Sees 2025 Adjusted Operating Profit Margin About 28.5% >DHR

Confronto tra pari

Modifica del prezzo

Danaher Corp Previsione

Obiettivo di Prezzo

By TipRanks

19.21% in crescita

Previsioni per 12 mesi

Media 238.13 USD  19.21%

Alto 275 USD

Basso 205 USD

Basato su 17 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Danaher Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

17 ratings

14

Acquista

3

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

189.8851 / 196.5Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Neutral Evidence

Sentiment

By Acuity

147 / 374 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.